Table 4.
Relationship between MTNR1B single-nucleotide polymorphism and 5-year overall survival of colorectal cancer patients
| No. of subjects | No. of cases (%) |
Crude
|
Adjusteda
|
|||
|
HR
|
95%CI
|
HR
|
95%CI
|
|||
| rs1387153 (C>T) | ||||||
| CC | 23 | 2 (11.8) | 1.00 | Referent | 1.00 | Referent |
| CT | 48 | 7 (41.2) | 1.65 | (0.34 to 7.95) | 1.98 | (0.40 to 9.82) |
| TT | 21 | 8 (47.1) | 6.03 | (1.28 to 28.4) | 10.6 | (1.87 to 59.5) |
| TT vs CC + CT | 4.18 | (1.61 to 10.9) | 6.23 | (2.01 to 19.3) | ||
| rs2166706 (T>C) | ||||||
| TT | 22 | 2 (11.1) | 1.00 | Referent | 1.00 | Referent |
| TC | 49 | 7 (38.9) | 1.55 | (0.32 to 7.47) | 1.91 | (0.39 to 9.45) |
| CC | 23 | 9 (50.0) | 5.74 | (1.24 to 26.6) | 10.5 | (1.96 to 56.4) |
| CC vs TT + TC | 4.15 | (1.65 to 10.5) | 6.40 | (2.21 to 18.6) | ||
| rs10830963 (C>G) | ||||||
| CC | 21 | 2 (11.1) | 1.00 | Referent | 1.00 | Referent |
| CG | 49 | 6 (33.3) | 1.19 | (0.24 to 5.91) | 1.40 | (0.27 to 7.22) |
| GG | 23 | 10 (55.6) | 5.79 | (1.27 to 26.5) | 9.46 | (1.90 to 47.1) |
| GG vs CC + CG | 5.09 | (2.01 to 12.9) | 7.43 | (2.63 to 21.1) | ||
| rs1447352 (A>G) | ||||||
| AA | 50 | 14 (77.8) | 1.00 | Referent | 1.00 | Referent |
| GA | 37 | 4 (22.2) | 0.36 | (0.12 to 1.08) | 0.31 | (0.10 to 0.99) |
| GG | 6 | 0 (0) | N/A | N/A | N/A | N/A |
| AA vs GG + GA | 3.37 | (1.11 to 10.2) | 4.28 | (1.32 to 13.9) | ||
a
Adjusted for age, sex, stage, adjuvant chemotherapy, tumor location and the methylation status of CDKN2A, MLH1 and MGMT gene. HR: Hazard ratio; N/A: Not applicable.